Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 27, 2023

BUY
$191.51 - $216.16 $8,809 - $9,943
46 Added 2.56%
1,844 $391,000
Q2 2023

Jul 24, 2023

SELL
$187.64 - $206.25 $403,425 - $443,437
-2,150 Reduced 54.46%
1,798 $346,000
Q1 2023

Apr 21, 2023

BUY
$127.59 - $203.08 $325,226 - $517,650
2,549 Added 182.2%
3,948 $799,000
Q1 2022

Apr 29, 2022

SELL
$119.61 - $157.85 $6,339 - $8,366
-53 Reduced 3.65%
1,399 $202,000
Q4 2021

Jan 19, 2022

BUY
$142.57 - $190.86 $97,375 - $130,357
683 Added 88.82%
1,452 $224,000
Q2 2021

Jul 29, 2021

SELL
$135.08 - $161.1 $20,262 - $24,165
-150 Reduced 16.32%
769 $121,000
Q1 2021

Apr 26, 2021

BUY
$137.51 - $190.8 $20,626 - $28,620
150 Added 19.51%
919 $128,000
Q4 2020

Jan 29, 2021

BUY
$164.63 - $211.93 $126,600 - $162,974
769 New
769 $135,000

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Whittier Trust CO Portfolio

Follow Whittier Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Whittier Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Whittier Trust CO with notifications on news.